Which has higher valuation and earnings, VCYT or TWST?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 9.12 $66.35M $1.09 54.25 Twist Bioscience $376.57M 15.52 -$77.67M -$1.33 N/A

Does the media refer more to VCYT or TWST?

In the previous week, Veracyte and Veracyte both had 10 articles in the media. Twist Bioscience's average media sentiment score of 0.71 beat Veracyte's score of 0.58 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TWST or VTRS more profitable?

Viatris has a net margin of -2.04% compared to Twist Bioscience's net margin of -19.85%. Viatris' return on equity of 19.04% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -19.85% -26.73% -19.15% Viatris -2.04% 19.04% 7.62%

Which has better valuation and earnings, TWST or GMAB?

Genmab A/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 15.52 -$77.67M -$1.33 N/A Genmab A/S $3.90B 4.59 $963M $1.32 21.76

Does the media refer more to TWST or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 11 mentions for Genmab A/S and 10 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.71 beat Genmab A/S's score of 0.34 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ASND or TWST?

In the previous week, Twist Bioscience had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Twist Bioscience and 8 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.76 beat Twist Bioscience's score of 0.71 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TWST or BBIO?

In the previous week, BridgeBio Pharma had 16 more articles in the media than Twist Bioscience. MarketBeat recorded 26 mentions for BridgeBio Pharma and 10 mentions for Twist Bioscience. BridgeBio Pharma's average media sentiment score of 0.72 beat Twist Bioscience's score of 0.71 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 10 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Twist Bioscience (TWST) Competitors

$93.85 +2.62 (+2.87%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$93.97 +0.12 (+0.13%)

As of 07/17/2026 07:40 PM Eastern

Compare

TWST vs. VCYT, VTRS, GMAB, ASND, and BBIO

Should you buy Twist Bioscience stock or one of its competitors? MarketBeat compares Twist Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Twist Bioscience include Veracyte (VCYT), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.

How does Twist Bioscience compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	9.12	$66.35M	$1.09	54.25
Twist Bioscience	$376.57M	15.52	-$77.67M	-$1.33	N/A

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Veracyte has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

In the previous week, Veracyte and Veracyte both had 10 articles in the media. Twist Bioscience's average media sentiment score of 0.71 beat Veracyte's score of 0.58 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte currently has a consensus target price of $55.88, suggesting a potential downside of 5.50%. Twist Bioscience has a consensus target price of $90.30, suggesting a potential downside of 3.78%. Given Twist Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Veracyte beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.

How does Twist Bioscience compare to Viatris?

Twist Bioscience (NASDAQ:TWST) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Twist Bioscience has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Twist Bioscience currently has a consensus target price of $90.30, indicating a potential downside of 3.78%. Viatris has a consensus target price of $17.50, indicating a potential upside of 1.21%. Given Viatris' higher possible upside, analysts plainly believe Viatris is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Twist Bioscience has higher earnings, but lower revenue than Viatris. Twist Bioscience is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	15.52	-$77.67M	-$1.33	N/A
Viatris	$14.56B	1.38	-$3.51B	-$0.26	N/A

In the previous week, Twist Bioscience had 10 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Twist Bioscience and 0 mentions for Viatris. Twist Bioscience's average media sentiment score of 0.71 beat Viatris' score of 0.59 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Twist Bioscience	Positive
Viatris	Positive

79.9% of Viatris shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viatris has a net margin of -2.04% compared to Twist Bioscience's net margin of -19.85%. Viatris' return on equity of 19.04% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Viatris	-2.04%	19.04%	7.62%

Summary

Twist Bioscience and Viatris tied by winning 8 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Genmab A/S?

Twist Bioscience (NASDAQ:TWST) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Genmab A/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	15.52	-$77.67M	-$1.33	N/A
Genmab A/S	$3.90B	4.59	$963M	$1.32	21.76

Genmab A/S has a net margin of 21.05% compared to Twist Bioscience's net margin of -19.85%. Genmab A/S's return on equity of 15.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Genmab A/S	21.05%	15.34%	8.94%

Twist Bioscience presently has a consensus price target of $90.30, indicating a potential downside of 3.78%. Genmab A/S has a consensus price target of $38.21, indicating a potential upside of 33.06%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

7.1% of Genmab A/S shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Genmab A/S had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 11 mentions for Genmab A/S and 10 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.71 beat Genmab A/S's score of 0.34 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Twist Bioscience has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Summary

Genmab A/S beats Twist Bioscience on 12 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Ascendis Pharma A/S has a net margin of 57.87% compared to Twist Bioscience's net margin of -19.85%. Ascendis Pharma A/S's return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Ascendis Pharma A/S currently has a consensus target price of $295.67, indicating a potential upside of 13.28%. Twist Bioscience has a consensus target price of $90.30, indicating a potential downside of 3.78%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Ascendis Pharma A/S has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

Twist Bioscience has lower revenue, but higher earnings than Ascendis Pharma A/S. Twist Bioscience is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.99	-$258M	$8.67	30.10
Twist Bioscience	$376.57M	15.52	-$77.67M	-$1.33	N/A

In the previous week, Twist Bioscience had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Twist Bioscience and 8 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.76 beat Twist Bioscience's score of 0.71 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Twist Bioscience on 12 of the 15 factors compared between the two stocks.

How does Twist Bioscience compare to BridgeBio Pharma?

Twist Bioscience (NASDAQ:TWST) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Twist Bioscience has a net margin of -19.85% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Twist Bioscience presently has a consensus price target of $90.30, suggesting a potential downside of 3.78%. BridgeBio Pharma has a consensus price target of $95.21, suggesting a potential upside of 16.99%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 16 more articles in the media than Twist Bioscience. MarketBeat recorded 26 mentions for BridgeBio Pharma and 10 mentions for Twist Bioscience. BridgeBio Pharma's average media sentiment score of 0.72 beat Twist Bioscience's score of 0.71 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Twist Bioscience has higher earnings, but lower revenue than BridgeBio Pharma. Twist Bioscience is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	15.52	-$77.67M	-$1.33	N/A
BridgeBio Pharma	$579.96M	27.48	-$724.93M	-$3.74	N/A

Twist Bioscience has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Summary

BridgeBio Pharma beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.84B	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-70.56	21.03	27.25	23.92
Price / Sales	15.52	167.28	513.66	89.44
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	11.97	8.26	10.69	6.18
Net Income	-$77.67M	$23.83M	$3.59B	$332.29M
7 Day Performance	3.54%	-3.47%	-2.20%	-2.05%
1 Month Performance	7.18%	2.69%	1.63%	-2.18%
1 Year Performance	166.85%	45.93%	25.64%	17.67%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	1.8974 of 5 stars	$93.85 +2.9%	$90.30 -3.8%	+166.8%	$5.84B	$376.57M	N/A	990	Analyst Forecast Gap Down
VCYT Veracyte	2.46 of 5 stars	$57.48 +0.9%	$51.86 -9.8%	+151.5%	$4.55B	$517.15M	52.73	790	Analyst Forecast Gap Down
VTRS Viatris	2.224 of 5 stars	$16.39 +0.7%	$17.50 +6.8%	+94.7%	$18.95B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.4797 of 5 stars	$28.80 -0.7%	$38.21 +32.7%	+31.3%	$18.08B	$3.72B	21.82	3,029	News Coverage Analyst Revision High Trading Volume
ASND Ascendis Pharma A/S	4.3126 of 5 stars	$265.22 -1.9%	$295.67 +11.5%	+53.6%	$16.87B	$814.57M	30.59	1,189	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. VCYT, VTRS, GMAB, ASND, and BBIO

How does Twist Bioscience compare to Veracyte?

Summary

How does Twist Bioscience compare to Viatris?

Summary

How does Twist Bioscience compare to Genmab A/S?

Summary

How does Twist Bioscience compare to Ascendis Pharma A/S?

Summary

How does Twist Bioscience compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. VCYT, VTRS, GMAB, ASND, and BBIO

How does Twist Bioscience compare to Veracyte?

Which has higher valuation and earnings, VCYT or TWST?

Is VCYT or TWST more profitable?

Which has more risk and volatility, VCYT or TWST?

Does the media refer more to VCYT or TWST?

Do analysts recommend VCYT or TWST?

Summary

How does Twist Bioscience compare to Viatris?

Which has more risk & volatility, TWST or VTRS?

Do analysts recommend TWST or VTRS?

Which has stronger earnings and valuation, TWST or VTRS?

Does the media refer more to TWST or VTRS?

Do institutionals and insiders believe in TWST or VTRS?

Is TWST or VTRS more profitable?

Summary

How does Twist Bioscience compare to Genmab A/S?

Which has better valuation and earnings, TWST or GMAB?

Is TWST or GMAB more profitable?

Do analysts recommend TWST or GMAB?

Do insiders and institutionals believe in TWST or GMAB?

Does the media refer more to TWST or GMAB?

Which has more volatility & risk, TWST or GMAB?

Summary

How does Twist Bioscience compare to Ascendis Pharma A/S?

Is ASND or TWST more profitable?

Do analysts recommend ASND or TWST?

Which has more volatility & risk, ASND or TWST?

Which has stronger valuation & earnings, ASND or TWST?

Does the media favor ASND or TWST?

Summary

How does Twist Bioscience compare to BridgeBio Pharma?

Is TWST or BBIO more profitable?

Do analysts rate TWST or BBIO?

Does the media refer more to TWST or BBIO?

Do institutionals and insiders have more ownership in TWST or BBIO?

Which has higher valuation & earnings, TWST or BBIO?

Which has more risk and volatility, TWST or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools